156 results about "Im injections" patented technology

The present disclosure relates to the expression of recombinant viral antigens using transgenic fungi. Compositions, production and administration of vaccines comprising those viral antigens are also disclosed. In some embodiments, these viral antigens can be used to formulate vaccines against Newcastle disease. These vaccines may be administered, for example, by intramuscular injection.

The invention relates to a method for stimulating an immune response by intramuscular injection of an artificial nucleic acid molecule comprising an open reading frame encoding an antigen and a 3′-UTR comprising at least two poly(A) sequences. The method may yield an increased immune response to the antigen or an increased neutralizing antibody response to the antigen.

The invention belongs to the technical field of aquaculture, and relates to a thioacetamide-induced procambarus clarkii hepatopancreas injury model construction and evaluation method and application thereof, and the method comprises the following steps: selecting healthy and temporarily cultured procambarus clarkii with the weight of 10.0 + / -1.45 g as an object for establishing the hepatopancreas injury model; fasting the procambarus clarkii for 12 hours, and then giving a thioacetamide solution, wherein the application dosage is 0.4-0.8 mg / g body weight; the thioacetamide is a thioacetamide solution which is prepared from a 0.9 wt% NaCl solution and has the concentration of 40 to 80 mg / mL; the mode of administration of the thioacetamide solution is intramuscular injection. The TAA is applied to construction of the hepatopancreas injury model of the procambarus clarkia for the first time, individual death is not induced in the model construction process, and an ideal experimental model capable of researching pathogenesis of hepatopancreas diseases and screening related therapeutic drugs is obtained. The method has the advantages of being short in period, low in cost, easy to operate, good in repeatability and the like.

The invention particularly relates to a diphtheria toxin antigen modified by fatty acid and application thereof, and belongs to the field of biological medicine, in the diphtheria toxin antigen modified by fatty acid, the fatty acid modification comprises N-terminal cysteine (Cys) modified by fatty acid, the N-terminal Cys modified by fatty acid is characterized in that sulfydryl containing Cys is modified by diacylglycerol and / or alpha amino is modified by fatty acyl. Compared with the existing diphtheria toxin protein antigen, the fatty acid modified diphtheria toxin antigen not only has faster induction and higher immune protection effect than the conventional intramuscular injection induction of the existing diphtheria toxin antigen, but also can induce respiratory tract mucosa immunity, and provides a basis for blocking diphtheria infection and diffusion propagation and providing a vaccine for immunoprophylaxis.

The invention discloses mannheimia haemolytica outer membrane vesicles as well as a preparation method and application thereof, and belongs to the technical field of bioengineering. The OMV is separated from Mh-5 strain culture supernatant through tangential flow ultrafiltration combined with an ultracentrifugation technology, and animal experiments prove that a high-level IgG / IgM antibody can be induced by intramuscular injection of 50 micrograms per mouse, expression of inflammatory factors such as IL-6 and TNF-alpha of the spleen is remarkably improved, the protection rate after challenge reaches 85.7%, and pathological damage is remarkably lighter than that of an inactivated vaccine group. According to the scheme provided by the invention, the problems of insufficient serotype coverage and antibiotic resistance in the prior art are solved, and a new strategy is provided for prevention and control of mannheimia haemolytica.

The invention discloses riemerella anatipestifer and application of the riemerella anatipestifer in an egg yolk antibody. The riemerella anatipestifer is named as BRA22A011, and the preservation number of the riemerella anatipestifer is CGMCC (China General Microbiological Culture Collection Center) No.45887. The invention also discloses an inactivated vaccine, wherein the antigen in the inactivated vaccine contains the inactivated riemerella anatipestifer BRA22A011. The invention further discloses an egg yolk antibody, and the egg yolk antibody is prepared by using the riemerella anatipestifer BRA22A011 as an antigen. The use mode of the egg yolk antibody is intramuscular injection inoculation, and the injection dosage is 0.5 mL. The riemerella anatipestifer BRA22A011 has high pathogenicity and strong immunogenicity, and the egg yolk antibody prepared from the riemerella anatipestifer BRA22A011 can replace antibiotics and vaccines, is safe, free of residues, free of drug resistance and environment-friendly, and has a good prospect in clinical application of preventing and treating infectious serositis of ducks. The riemerella anatipestifer BRA22A011 and the Escherichia coli BE-20261 are adopted for preparing the egg yolk antibody together, and the prevention and treatment effects of the egg yolk antibody are more obvious.

The invention relates to a batch production method capable of optimizing the sow delivery induction process and improving the delivery concentration ratio. Comprising the following steps: S1, determining an expected date of confinement of a sow; s2, injecting cloprostenol sodium into the pudendum of the sow in the morning one day before the expected date of confinement; s3, performing intramuscular injection of carbetocin for the sows in the morning of the expected date of confinement. According to the method, potential adverse effects of childbirth induction are deeply studied, the optimal time and dosage for combined use of cloprostenol sodium and beioxytocin are determined, childbirth induction for batch production of sows is optimized, the childbirth time of the sows is concentrated in the working time of a pig farm, the labor efficiency is improved, and the labor intensity is reduced.

The invention relates to a method of treating or preventing a disease or condition comprising administering a therapeutically effective amount of a psychedelic compound to a patient by intramuscular injection. Uses, formulations and kits are also described.

The invention relates to the technical field of biological medicine, and discloses a nanoparticle vaccine based on an HER2 target spot and application of the nanoparticle vaccine, and the nanoparticle vaccine based on the HER2 target spot comprises an HER-2 gene related antigen sequence HER2 and hepatitis B core virus-like particle nanoparticles HBc VLPs; the amino acid sequences of the gene are respectively shown as SEQ ID No. 1 and SEQ ID No. 2. According to the invention, hepatitis B core virus-like particles are modified by using B cell epitopes of HER2 targets, and the nanoparticle tumor vaccine suitable for intramuscular injection is prepared. The vaccine aims at reducing clinical safety risks and reducing immune tolerance and toxic and side effects caused by long-term use of monoclonal antibody drugs. Through an active immunization mode, an organism can continuously generate an anti-HER2 specific antibody, and clinical guidance is provided for research and development of therapeutic general tumor vaccines.

The invention relates to the technical field of animal husbandry, in particular to a synchronous oestrus-timing insemination method suitable for cattle, which comprises the following steps: firstly, performing intramuscular injection of PG (cloprostenol sodium) at different time points after calving to promote uterine recovery and luteolysis and lay a synchronous oestrus foundation; the method comprises the key steps that GnRH (gonadotropin release hormone) is given through intramuscular injection on the 43rd day, the 53rd day, the 60th day and the 69th day, pituitary is promoted to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), collection and screening of follicles are guided, follicle maturation is promoted, the oestrus uncovering rate and the oestrus conception rate are increased, a melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day, and the melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day. The synthesis of ovarian hormones is promoted by regulating the hypothalamus-pituitary-gonad axis, the secretion of follicle cell factors and maturation promoting factors is promoted, the development of granular cells is promoted, and the maturation of oocytes is promoted. According to the method, the pregnancy rate of a double-synchronization-timing insemination scheme which is most widely used in a large-scale dairy cow breeding pasture at present can be remarkably increased, and feasible technical support is provided for success of increasing the breeding efficiency of cows.

The invention discloses an electric local anesthetic injection device and relates to the technical field of medical instruments, a fixed sliding rail is mounted at the top of a rotating flat head, fixed sliding blocks are slidably mounted at two ends in the fixed sliding rail, a bidirectional screw is rotatably mounted in the fixed sliding rail, a clamping plate is connected to the top of each fixed sliding block, and a handle is clamped in the middle of the clamping plate; a limiting sliding groove is formed in one end of the top of the handle, a fixing frame is installed at the other end of the top of the handle, a heat preservation electric heating plate is installed at the bottom of the fixing frame, and an injector is placed at the top of the fixing frame. The labor intensity of anesthetists is greatly reduced, when intramuscular injection is carried out on a patient, a needle head can be rapidly positioned, injection is convenient and fast, electric quantitative injection can also be carried out, two operation modes are adopted, and the anesthetic syringe is suitable for being used under different conditions, more comprehensive and reasonable in operation and suitable for being used and popularized.

Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.

This invention provides a modified BoNT / A for treating facial wrinkles, wherein the modified BoNT / A is administered via intramuscular injection at multiple sites on an individual's face, wherein the modified BoNT / A is administered at a unit dose of greater than 1754 pg or greater than 8000 pg per site, wherein the multiple sites are selected from: up to two sites on the corrugator supercilii muscle and one site on the depressor supercilii muscle for treating glabellar lines; up to five sites on the frontalis muscle for treating forehead wrinkles; and up to three sites on the orbicularis oculi muscle for treating lateral canthal wrinkles, wherein the total dose of modified BoNT / A administered during treatment is up to 264,000 pg (and optionally greater than 88,000 pg), and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N The structure domain), and the BoNT / B receptor binding domain (H C (structural domain).

The present invention relates to aqueous saline solutions comprising dantrolene and optionally at least one additional active ingredient, such as botulinum neurotoxin, and their use for various therapeutic and / or aesthetic purposes. The solutions can be administered in any suitable manner, but have the advantage of being particularly well-suited for intramuscular injection.

Compounds comprising antiviral prodrugs, and pharmaceutical formulations comprising the compounds, which can be orally bioavailable or formulated for intramuscular injection. Methods for making compounds such as antiviral prodrugs. Methods for treating coronavirus and other RNA viral infections in mammals. Methods for producing pharmaceutical triphosphates.

The utility model belongs to the field of medical instruments, and particularly relates to a fulvestrant intramuscular injection positioning ruler which comprises a long fixed ruler, two short shifting rulers and two arc-shaped pieces, and the two short shifting rulers are located on the two sides of the long fixed ruler respectively and rotationally connected with the long fixed ruler; the two arc-shaped pieces are symmetrically distributed on the two sides of the long fixed ruler, one side of each arc-shaped piece is fixedly connected with the long fixed ruler, the other side of each arc-shaped piece is fixedly connected with the short shifting ruler, an arc-shaped notch is formed in the inner side of each arc-shaped piece, and a plurality of positioning holes are formed in each arc-shaped piece. The fulvestrant injection device is directly aligned with the highest point of iliac spine and the peak of hip fissure of a human body through the positioning rule in one step, compared with operation modes such as a cross method and a line connection method, the time for manual searching and positioning is saved, meanwhile, injection of fulvestrant is completed in the positioning hole, and the injection efficiency is improved. And injection errors and complications caused by non-professional operation methods, inaccurate manual positioning, repeated part injection and the like are solved, so that the injection pain of a patient is reduced, and the treatment compliance and the life quality are improved.

An embodiment of the present invention provides a biocompatible, thermosensitive hydrogel composition for subcutaneous or intramuscular injection, the hydrogel comprising a poloxamer, such as poloxamer 338, poloxamer 188, or poloxamer 407, or a mixture thereof, and the composition includes a therapeutic protein or antigen embedded in the composition for sustained release.

The present invention relates to aqueous compositions comprising dantrolene and optionally also at least one additional active principle, such as botulinum neurotoxin, and their use for various therapeutic and / or aesthetic / cosmetic purposes. The compositions can be administered in any suitable way but are advantageous in that they are particularly well adapted to intramuscular injection, subcutaneous injection and / or intradermal injection.

The invention relates to an external ointment for wound treatment, which is mainly used for treating burns and scalds and also used for treating skin soft tissue injury caused by other reasons such as acid-base corrosion, skin soft tissue injury and the like. The traditional Chinese medicine belongs to a wet bandaging therapy, and has the advantages of good effect, stable medicine property, no toxic or side effect, simplicity, feasibility, low price, no injury surface exposure, mobility of a patient during treatment, no obvious scar formation without skin grafting, easy acceptance by the patient and the like if the medicine needs to be carefully changed. Intravenous injection or intramuscular injection or oral administration of a critical patient such as replenishment liquid acid-base balance anti-infection and the like needs to be carried out simultaneously, so that the aim of curing can be achieved.

The invention discloses a dexketoprofen trometamol nasal spray and a preparation method thereof, a buffering agent is used as a stabilizer, and the dexketoprofen trometamol nasal spray which is good in stability, small in irritation, convenient, rapid in effect taking and extremely small in side effect is provided, so that the medication compliance of patients and the convenience of clinical medication are improved; after being administrated, the nasal spray can be quickly absorbed through nasal mucosa, the absorption speed is equivalent to that of intramuscular injection, the nasal spray can quickly reach the peak concentration as intramuscular injection, and the curative effect can be quickly exerted; the preparation has the advantages of no first-pass effect during nasal mucosa administration, high bioavailability and rapid absorption, is suitable for self-rapid analgesia, and is stable in process and suitable for large-scale production.

The present application relates to a kind of cat rhinotracheitis, feline calicivirus disease, cat pancytopenia triple subunit vaccine, preparation method and its application.The present application is expressed antigen protein using CHO cell strain, and synergistic effect is combined molecular adjuvant (IL-2, GM-CSF, CpG) with MF59 nanoemulsion, molecular adjuvant composition is adsorbed on the surface of MF59 nanoemulsion, then embedded in polylactic acid-glycolic acid copolymer microsphere, mixed with triple subunit protein to form vaccine preparation.The vaccine prepared in the present application can stimulate humoral immunity and cellular immunity simultaneously by subcutaneous or intramuscular injection, significantly improve antibody titer and attack protection rate, prolong immune protection period, and reduce injection site adverse reactions.The synergistic effect of protein and molecular adjuvant and MF59 makes the vaccine superior to traditional subunit vaccine in safety, stability and immunological efficacy, and is suitable for high-efficiency prevention of three viral infectious diseases in feline.

The invention relates to an artificial intelligence-based decision support method for determining the sciatic nerve prior to intramuscular injection and enabling safe injection.

The invention belongs to the technical field of pharmaceutical preparations and preparation thereof, and discloses a sustained-release type chlorsulfuron nano preparation, and every 100 g of the preparation comprises the following components by weight: 0.1 to 5.0 g of chlorsulfuron, 0.5 to 3.5 g of myristyl alcohol, 3.0 to 9.0 g of fir oil, 1.0 to 5.0 g of ethyl acetate, 3.0 to 6.0 g of polyoxyethylene (2) oleyl alcohol ether, 8.0 to 20.0 g of tween-20, 1.0 to 2.0 g of xylitol, 0.01 to 0.1 g of triethanolamine, and the balance of water for injection. After intramuscular injection, the medicine is slowly released in a tissue local part, a long-acting effect can be achieved, the administration frequency is reduced, and the animal stress reaction is reduced. And meanwhile, the particle size of the medicine is distributed at a nanometer level, so that the bioavailability is greatly improved. The invention further discloses a preparation method, and the preparation method does not need special equipment, can be converted in a common workshop, and has a wide market prospect.

The present invention relates to aqueous pharmaceutical formulations, methods for their production, and uses thereof. The aqueous pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound and water, with a pH from 5 to 6.5, preferably from about 5 to about 6, and a concentration of the optionally substituted dimethyltryptamine compound of about 10 mg / ml or greater as the freebase equivalent. These formulations can comprise an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 5 ml or less. Such formulations are surprisingly suitable both for intramuscular injection and nebulised inhalation, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.

The invention relates to the technical field of mRNA vaccine research and development, and discloses a Tp0136T cell epitope mRNA vaccine based on lipid nanoparticle delivery and application of the Tp0136T cell epitope mRNA vaccine in syphilis prevention, the vaccine contains an mRNA sequence and an LNP delivery system, the mRNA sequence contains a Tp0136T1T cell epitope coding region (amino acid L477-S486, optimized by codon), a Cap 1 structure, optimized UTR and poly (A) tails of 65-76 adenosine, and psi or m5C is used for replacing trona; the LNP is prepared from SM-102, DSPC (Distearoyl Pyrrolidone), cholesterol and DMG-PEG (Dimethyl Glycol-Polyethylene Glycol) according to a molar ratio of 50 The particle size of the vaccine is less than or equal to 150nm, PDIlt; 0.2, the Zeta potential is-5 to-15 mV, and the encapsulation efficiency is greater than or equal to 93.47%. The preparation method comprises the steps of mRNA design synthesis, mRNA-LNP preparation characterization and in-vitro expression verification, through intramuscular injection inoculation, strong Th1 type and CD8 + CTL immune response can be induced, treponema pallidum load and skin ulcer rate can be reduced, and the method can be used for syphilis prevention.

The application provides a kind of medicine composition for treating muscle and bone disease and its application, belong to medical technology field.The medicine composition includes the following weight parts components: compound angelica injection 5-10 parts, kadsura injection 5-10 parts, wild medlar injection 5-10 parts, methylcobalamin injection 5-10 parts;It can also be selectively added vitamin B1 injection, vitamin B12 injection, yellow Chinese wax injection or bone peptide injection.The composition of the application is administered by acupoint injection or intramuscular injection, utilizes the synergistic effect of multiple traditional Chinese medicine injection and western medicine injection, reaches the comprehensive treatment effect of promoting blood circulation to remove blood stasis, dispelling wind to stop pain, nerve nutrition.Clinical experiments show that the application has significant effect on lumbar disc herniation, cervical spondylosis, shoulder periarthritis, knee osteoarthritis, femoral head necrosis, osteoporosis and the like, and the total effective rate is more than 95%, with fast effect, low recurrence rate, and no hormone-related side effects, suitable for patients of all ages.

The invention discloses a comprehensive automatic immunization all-in-one machine which comprises a machine base, and a controller, a poultry intramuscular injection device, a poultry neck posterior subcutaneous injection device, a poultry wing membrane stabbing device and a poultry eye drop immunization device which are arranged on the machine base, the poultry intramuscular injection device, the poultry posterior-neck subcutaneous injection device, the poultry eye drop immunization device and the poultry wing membrane stabbing device are controlled by the controller, the poultry intramuscular injection device is used for performing intramuscular injection on poultry, and the poultry posterior-neck subcutaneous injection device is used for performing posterior-neck subcutaneous injection on poultry; the poultry eye dropping immunization device is used for carrying out eye dropping operation on poultry, and the poultry wing membrane stabbing device is used for carrying out stabbing injection on wing membranes of the poultry. The situation that traditional artificial immunization is high in labor intensity and low in efficiency is changed, the work efficiency of immunization inoculation is greatly improved, and meanwhile the equipment purchase cost and the site occupied area are reduced; moreover, the poultry grabbing frequency is reduced, the irritability is reduced, and the timeliness and continuity of immunization are improved.

The invention discloses nucleotide of fusion protein for coding neutrophil elastase and application of the nucleotide. A nucleotide sequence for coding the fusion protein is as shown in SEQ ID NO. 8; the nucleotide sequence of mRNA (messenger ribonucleic acid) for coding the fusion protein is as shown in SEQ ID NO. 12; the fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment. The mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the wild type ELANE can achieve a tumor elimination effect only by complex intratumor injection. According to the mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the ELANE fusion protein, tumor elimination in a mouse body can be realized only through intramuscular injection administration, the operation is simpler and more convenient, and the mRNA preparation is beneficial to treatment of scattered and tiny tumor focuses in the body.

The invention provides a recombinant respiratory syncytial virus vaccine as well as a preparation method and application thereof, and belongs to the technical field of viral vaccine preparations. Wherein the recombinant respiratory syncytial virus vaccine is a vaccine preparation in a liquid dosage form comprising pre-F protein antigen; wherein the amino acid sequence of the pre-F protein antigen is any one of the amino acid sequences as shown in SEQ ID NO. 1 to SEQ ID NO. 3. The recombinant respiratory syncytial virus vaccine provided by the invention is a liquid vaccine preparation comprising a recombinant respiratory syncytial virus (RSV) protein stock solution, the vaccine preparation has better stability, and the self-made recombinant respiratory syncytial virus vaccine is proved to have good immunogenicity through immune experiment research on a BALB / c mouse by intramuscular injection.

Briefly, an injection delivery system is described for subcutaneous or intramuscular injection of a drug, in particular a large volume of a biologic drug, high and low viscosity biologies, or a large volume of a high viscosity and low viscosity chemical drug. The injections may be self-administered or performed by a caregiver. The system uses a pump to move a drug from a vial, thorough an infusion set, and into the patient. A vial of a biological or chemical drug is set into a vial adapter that is associated with the pump, which can be manual or powered. A fluidics subassembly connects the vial adapter, pump, and the infusion set so that a drug pathway is enabled from the vial to the patient. The fluidics subassembly has one or more check valves to assure that the drug pathway is only enabled for a one-way drug flow out of the vial and to the patient. The infusion set has flexible tubing that connects the fluidics subassembly to cannula assembly inside an infuser housing. The cannula assembly has an air evacuation assembly near the tip of the needle. This air evacuation assembly is constructed to safely exhaust air from the cannula assembly at three times: (1) at initial setup to exhaust air while the drug is filling the cannula assembly, which enables the self-priming; (2) during injection to exhaust drug-entrapped air, which increases injection safety; and (3) at the end of drug delivery to exhaust air after the full dose of drug has been delivered to the cannula assembly, including drug that was in the tubing, which reduces wasted drug and minimizes the amount of drug overfill required in the vial.